{"article_title": "Amgen Myeloma Drug Kyprolis Fails Clinical Trial", "article_keywords": ["fails", "trialthe", "refractory", "relapsed", "treated", "survival", "myeloma", "drug", "amgen", "trial", "clinical", "kyprolis", "study", "response", "subsidiary", "regimen"], "article_url": "http://www.wsj.com/articles/amgen-myeloma-drug-kyprolis-fails-clinical-trial-1407963217", "article_text": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed and advanced refractory multiple myeloma in a late-stage clinical trial.\n\nThe 315-patient, open-label study evaluated the response from those treated with Kyprolis compared with those who received an active control regimen of low-dose...", "article_metadata": {"article.template": "snippet", "article.created": "2014-08-13T20:53:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed multiple myeloma in a late-stage clinical trial.", "title": "Amgen Myeloma Drug Kyprolis Fails Clinical Trial", "image": {"alt": "Amgen's myeloma drug Kyprolis failed to meet its primary endpoint in a trial", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "creator": "@mjarmental", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304644204580090011313364970&headline=Amgen%26apos%3Bs%20myeloma%20drug%20Kyprolis%20failed%20to%20meet%20its%20primary%20endpoint%20in%20a%20trial&weburl=http://www.wsj.com/articles/SB10001424052702304644204580090011313364970"}}, "page.site.product": "WSJ", "keywords": "amgen,cancer drugs,cancer treatments,clinical trials,kyprolis,onyx pharmaceuticals,Amgen,AMGN,Onyx Pharmaceuticals,regulation,government policy,regulatory bodies,new products,services,corporate,industrial news,official trials,tests,biotechnology,pharmaceuticals,health care,life sciences,biopharmaceuticals,drugs,medication,drug discovery,development,prescription drugs", "news_keywords": "amgen,cancer drugs,cancer treatments,clinical trials,kyprolis,onyx pharmaceuticals,Amgen,AMGN,Onyx Pharmaceuticals,regulation", "article.headline": "Amgen's myeloma drug Kyprolis failed to meet its primary endpoint in a trial", "description": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed multiple myeloma in a late-stage clinical trial.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304644204580090011313364970&headline=Amgen%26apos%3Bs%20myeloma%20drug%20Kyprolis%20failed%20to%20meet%20its%20primary%20endpoint%20in%20a%20trial&weburl=http://www.wsj.com/articles/SB10001424052702304644204580090011313364970", "user.type": "nonsubscriber", "testkeys": "C", "article.page": "Business", "article.summary": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed multiple myeloma in a late-stage clinical trial.", "page.site": "wsj", "page.content.format": "responsive", "article.published": "2014-08-13T22:31:00.000Z", "dj.asn": "i-f262", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "word_count": 295, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed multiple myeloma in a late-stage clinical trial.", "title": "Amgen Myeloma Drug Kyprolis Fails Clinical Trial", "url": "http://www.wsj.com/articles/amgen-myeloma-drug-kyprolis-fails-clinical-trial-1407963217", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Maria Armental", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Amgen Myeloma Drug Kyprolis Fails Clinical Trial", "article.type": "Business", "article.id": "SB10001424052702304644204580090011313364970", "user.exp": "default", "article.updated": "2014-08-13T22:31:00.000Z"}, "_id": "\"57477af46914bd0286fde5a7\"", "article_summary": "Amgen Inc. and its subsidiary Onyx Pharmaceuticals said on Wednesday that their Kyprolis cancer drug failed to meet its primary endpoint of improving overall survival for patients with relapsed and advanced refractory multiple myeloma in a late-stage clinical trial.\nThe 315-patient, open-label study evaluated the response from those treated with Kyprolis compared with those who received an active control regimen of low-dose..."}